Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
Real-time Estimate Cboe BZX  -  02:30 2022-11-28 pm EST
49.09 USD   -1.21%
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wedbush Maintains Forecast
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel« for the Treatment of Postsurgical Pain in Children Aged 6 or Older

09/20/2022 | 08:00am EST

Pacira BioSciences, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for an expanded indication of EXPAREL to include use in children aged 6 years and older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds. The European Commission approval was based on the results of the Phase 3 PLAY study of EXPAREL infiltration in pediatric patients undergoing spinal or cardiac surgeries. Overall findings were consistent with the pharmacokinetic and safety profiles for adult patients with no safety concerns identified at a dose of 4 mg/kg.

The PLAY study enrolled 98 patients to evaluate safety and the pharmacokinetics of EXPAREL for two patient groups: patients aged 12 to less than 17 years and patients aged 6 to less than 12 years. The European Commission decision is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. The data is still under review in the United Kingdom.

EXPAREL was initially approved by the European Commission in November 2020 as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
PACIRA BIOSCIENCES, INC. -1.03% 49.19 Delayed Quote.-17.42%
UK 10Y CASH -0.01% 3.1303 Delayed Quote.246.00%
All news about PACIRA BIOSCIENCES, INC.
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wed..
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
11/14Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2..
GL
11/14Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2..
GL
11/08Pacira BioSciences to Present at Two Healthcare Conferences in November
GL
11/07BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Marke..
MT
11/04HC Wainwright Adjusts Price Target on Pacira BioSciences to $76 From $83, Maintains Buy..
MT
11/04RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating
MT
11/04Wedbush Lowers Pacira BioSciences' Price Target to $88 From $94, Keeps Outperform Ratin..
MT
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 677 M - -
Net income 2022 47,0 M - -
Net Debt 2022 510 M - -
P/E ratio 2022 51,9x
Yield 2022 -
Capitalization 2 280 M 2 280 M -
EV / Sales 2022 4,12x
EV / Sales 2023 3,25x
Nbr of Employees 697
Free-Float 98,9%
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 49,69 $
Average target price 73,55 $
Spread / Average Target 48,0%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.-17.42%2 280
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY32.23%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555